Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016
September 20 2016 - 08:00AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announced that the Company will file its financial results for the
three and six months ended June 30, 2016 on Form 6K with the U.S.
Securities and Exchange Commission (“SEC”) after the closing of the
U.S. financial markets on September 26, 2016. The Form 6K will
include unaudited consolidated financial statements, as well as
additional information regarding the Company. The Form 6K will be
available at www.sec.gov and at www.rosettagenomics.com.
Kenneth A. Berlin, President and Chief Executive Officer of
Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of
Rosetta Genomics, will host a conference call on Monday, September
26, 2016 at 4:30 p.m. Eastern time to provide an update on the
Company’s business and respond to questions.
Individuals interested in listening to the conference call may
do so by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 82293939. The call is also
being webcast, and can be accessed on the investor relations
section of the Company’s website at www.rosettagx.com.
A telephone replay will be available through October 2, 2016 by
dialing (855) 859-2056 or for international callers (404) 537-3406,
and entering the Conference ID number 82293939. The webcast will be
available on the Company’s website for 30 days following the
completion of the call.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s most recently filed Annual Report on Form 20-F, as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160920005612/en/
Rosetta Genomics:Ken Berlin, (267) 298-1159President
& CEOinvestors@rosettagx.comorRosetta
Genomics Investor:LHAAnne Marie Fields, (212)
838-3777afields@lhai.co
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2023 to Mar 2024